Lung Cancer

Increases in the TP53 mutation in African American men with tobacco-related cancers may be responsible for chemotherapy resistance and a poorer prognosis overall.

Osimertinib demonstrated clinically meaningful progression-free survival benefit in EGFR mutation–positive NSCLC compared with current standard of care.

Researchers in Spain discovered a strange side effect of PD-L1 immunotherapy in some NSCLC patients-hair repigmentation-that may be a good response marker for this treatment.

This video reviews the role of surgery in patients with stage III (N2) non–small-cell lung cancer, highlighting some of the challenges in studying these patients and the need for multidisciplinary patient evaluations.

Computed tomography (CT) screening for lung cancer could lead to increased rates of smoking cessation in a high-risk population, with this “teachable moment” extending even to those with negative scan results.

Five-year results of a single-institution study show that proton beam radiotherapy given concurrently with chemotherapy offers promising clinical outcomes with good toxicity results compared with historical data.

A phase III trial failed to demonstrate superiority of eribulin over treatment of physician’s choice in patients with heavily pretreated non–small-cell lung cancer.

This video reviews pseudoprogression in non–small-cell lung cancer, including the incidence of this phenomenon and treatment considerations when it arises.

This video reviews the use of PD-L1 testing in selecting patients for frontline lung cancer treatment with pembrolizumab and examines which patients might not be appropriate for immunotherapy.

Once-daily RT given concurrently with chemotherapy showed no difference in survival compared with the twice-daily standard in small-cell lung cancer.

Holocaust survivors have a small but consistent increase in the risk of developing cancer, in particular colorectal and lung cancers.

Proton-beam therapy was found to be safe for patients with limited-stage small-cell lung cancer in the first prospective registry study of the therapy, with only a small number of high-grade toxicities.

This video reviews immunotherapy options now available for the treatment of lung cancer across different lines of therapy.

Nivolumab did not extend progression-free survival over chemotherapy in the first-line setting in patients with PD-L1–positive advanced non–small-cell lung cancer, according to results of an open-label phase III trial.

This video highlights a study that tested an alternative maintenance strategy determined by response to induction chemotherapy for patients with advanced non-squamous non–small-cell lung cancer.

A subpopulation of T cells called tissue resident memory cells may be able to determine which cancer patients' immune systems can mount an effective anti-tumor response

The FDA has approved dabrafenib in combination with trametinib for the treatment of BRAF V600E mutated non-small cell lung cancer.

Dr. Kim discusses why non-small cell lung cancer should be considered the paradigm for precision medicine, and how treatment of the disease has changed over the last decade.

Adding nintedanib to pemetrexed/cisplatin improved the progression-free survival of patients with malignant pleural mesothelioma compared with placebo.

In this podcast interview, Dr. Hossein Borghaei discusses some of the latest science presented at ASCO that focuses on immunotherapy in lung cancer.

The PD-L1 inhibitor atezolizumab showed substantial responses as a single-agent treatment in patients with advanced non–small-cell lung cancer with confirmed PD-L1 expression.

Adding palifosfamide to carboplatin and etoposide failed to improve survival over the latter two agents alone in patients with extensive-stage small-cell lung cancer.

The American Society for Radiation Oncology issued a new clinical guideline for the use of stereotactic body radiation therapy in patients with early-stage lung cancer.

Treatment with nivolumab alone and in combination with ipilimumab resulted in durable responses in patients with previously treated small-cell lung cancer.

Three randomized trials of SBRT vs surgical resection closed due to poor accrual, but an analysis of patients treated in these trials suggested that SBRT might even be superior to surgery. New trials are underway to further assess the question of whether SBRT can be the definitive treatment for early-stage NSCLC instead of surgery.

In this interview we discuss the role of checkpoint inhibitors in advanced lung cancer and treatment strategies when patients progress.

This video examines how a change to weight-based pembrolizumab dosing in first-line PD-L1–positive lung cancer could save nearly $1 billion in US healthcare costs.

The second-generation ALK-inhibitor alectinib should be the new standard of care for first-line treatment of ALK-positive non–small-cell lung cancer, according to a new study.

The use of prophylactic cranial irradiation (PCI) reduced the incidence of symptomatic and asymptomatic brain metastases in patients with radically treated stage III NSCLC. The therapy did not, however, improve overall survival, and decreased quality of life.

Lorlatinib exhibits durable responses in patients with ALK-positive non–small-cell lung cancer and robust intracranial activity in those with brain metastases.